Abstract
This overview will provide the reader with summarised information about darunavir, a new protease inhibitor licenced for the treatment of drug resistant HIV-infection. Darunavir is a promising new drug with good clinical efficacy data and safety profile. In this overview clinicians will be updated on clinical efficacy data, side-effects, resistance profile and drug interactions. The overview should give clinicians a sound understanding of when and how to use this new protease inhibitor in the treatment of HIV-infection.
Original language | English |
---|---|
Pages (from-to) | 235-241 |
Number of pages | 7 |
Journal | Sexual Health |
Volume | 5 |
Issue number | 3 |
DOIs | |
Publication status | Published - 20 Aug 2008 |
Keywords
- Drug resistance
- HAART
- Prezista
- Protease inhibitor